Just published! Peer reviewed paper on our lead product candidate, axalimogene filolisbac, for cervical, anal, and head and neck cancers.
In the News
Blood Protein Levels May Predict Cervical Cancer Patients Likely to Benefit from Advaxis’ Immunotherapy
Review article illustrating mechanism of action of axalimogene filolisbac and the scientific validity of using Listeria monocytogenes (Lm) as an immunotherapeutic bacterial vector published in peer-reviewed journal